Published On: 8/24/2020
TARGET-NASH Expands to Europe, Enrolls First Participant
Target RWE, an innovative health evidence solutions company generating real-world evidence (RWE) and delivering regulatory-grade data to partners to advance clinical, medical, and commercial outcomes, has announced its nonalcoholic steatohepatitis (NASH) longitudinal study, TARGET-NASH, has enrolled its first European patient.
“Our TARGET-NASH study continues to grow and lead real-world evidence generation in NASH. TARGET-NASH enrolling its first European patient is an important step forward and will provide important perspectives for our key stakeholders on this growing health concern,” said Target RWE CEO Neal Bibeau.
Launched in 2016, TARGET-NASH is an observational study of more than 5,000 participants diagnosed with nonalcoholic fatty liver disease (NAFLD). Target RWE’s network of sites includes both community and academic centers and enrolls adult and pediatric participants across the spectrum of this liver disease. Once enrolled, three years of retrospective data and five years of prospective data is collected from TARGET-NASH participants, including Patient-Reported Outcomes (PRO) and biorepository samples.
The TARGET-NASH dataset is critical to providing a baseline and measuring the impact of current practice guidelines, management, and new therapies utilized for patients with medical co-morbidities, hepatic, cardiovascular, and/or other endocrine-associated outcomes.
TARGET-NASH was the first study established by Target RWE when the company was created in 2015. Target RWE has added seven additional studies to its portfolio since then including: hepatocellular carcinoma (HCC), inflammatory bowel disease (IBD), primary biliary cholangitis (PBC), immune-mediated inflammatory skin conditions (DERM), chronic hepatitis B (HBV), asthma, and COVID-19.
About Target RWE
Headquartered in Durham, NC, Target RWE is an innovative health evidence solutions company generating real-world evidence (RWE) and delivering regulatory-grade data to partners to advance clinical, medical, and commercial outcomes as well as to improve patient health guidelines and quality of care.
Target RWE has developed a turnkey health evidence solution which rapidly aggregates real-world data (RWD) from a large network of participating sites (academic and community) across the United States, Europe and other non-U.S. locations. Target RWE’s datasets are aggregated from various data sources including registries, electronic medical records, patient outcomes measures, biospecimen analyses, and claims databases. Whether partners need consulting services, datasets, support for custom solutions or access to a large biorepository of disease agnostic patient samples, Target RWE strives to be the preferred choice.
For more information, visit www.targetrwe.com.
Contact:
Kayla Slake
Marketing Manager
984.234.0268 ext 205
More News
-
11/28/2020
TARGET-DERM Objectives Published in BMJ Open -
11/13/2020
Target RWE Data Presented at AASLD Virtual Meeting Provides Important Updates for NASH and PBC Communities -
10/01/2020
TARGET-DERM Real-World Study Success Leads To Global Site Expansion And New Dermatologic Conditions -
09/24/2020
TARGET-NASH Data Publication Finds Nearly One In Five Patients With NAFLD Have Prior Prescription Opioid Use -
09/09/2020
Asian Lean Patients With NAFLD Are 53% Less Likely To Have Cirrhosis, Cardiovascular, And Metabolic Diseases - Latest Data Findings Released From TARGET-NASH Study